Search Results
Aug 25, 2025, 14:04 ET Zillow unveils Unlock conference for agents: A gathering where real estate's boldest thinkers build what's next
need to manage the moment and lead in their communities. "Unlock is where the future of the industry takes shape," said Jun Choo, Zillow chief operating officer. "Unlock has evolved from an invitation-only gathering for select agent partners into a forward-looking industry
More news about: Zillow
Aug 22, 2025, 09:00 ET Diagnóstico precoce e tratamento adequado podem evitar 1,6 milhão de mortes por doença renal crônica e reduzir pela metade a necessidade de diálise no Brasil1
al. THE ENVIRONMENTAL IMPACT OF CHRONIC KIDNEY DISEASE INTERNATIONALLY: RESULTS OF A LIFE CYCLE ASSESSMENT. Nephrol Dial Transplant. 2023 Jun;38(Suppl 1):gfad063c_2695. doi:10.1093/ndt/gfad063c_2695Whaley-Connell A, et al. The importance of early identification of chronic kidney disease.
More news about: AstraZeneca
Aug 22, 2025, 03:04 ET Talkpool Q2 Interim Report Apr-Jun 2025
https://news.cision.com/talkpool-ag/r/talkpool-q2-interim-report-apr-jun-2025,c4221666 The following files are available for download:
More news about: TalkPool AG
Aug 21, 2025, 10:28 ET Mais colágeno e elastina: quais produtos e procedimentos ajudam a preservar essas proteínas tão preciosas para a pele?
Volk A, Daro-Kaftan E. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013 Jun;39(6):915-22.7. Morgan P, et al. Product Manufacturing Process for Poly-L-lactic acid (PLLA-SCA). Poster presented at IMCAS World Congress,
More news about: Galderma
Aug 21, 2025, 08:00 ET BioDlink's Bevacizumab Approved for Market Launch in Indonesia, Marking Fourth Consecutive Emerging Market Authorization
expansion in Southeast Asia and Latin America.Dr. Jun Liu, Chief Executive Officer and Executive Director of BioDlink, stated:"These consecutive approvals demonstrate the strength of
More news about: BioDlink Biopharm Co., Ltd.
Aug 21, 2025, 01:00 ET GC Biopharma's Study on Hunterase Lysosomal Delivery Mechanism Published in SCIE-Indexed Journal
[email protected] Yelin Jun[email protected] Yoonjae Na
More news about: GC Biopharma
Aug 20, 2025, 09:45 ET Belotero® da Merz Aesthetics® comemora 20 anos de sucesso mundial
(ISAPS). Global Survey 2023: Full report and press releases [online]. Mount Royal, NJ: ISAPS; 12 jun. 2024. Disponível em:
More news about: Merz Aesthetics® Brasil
Aug 20, 2025, 07:55 ET Kingsoft Cloud Announces Unaudited Second Quarter 2025 Financial Results
Jun 30,2025 Jun 30,2024 Jun 30,2025
More news about: Kingsoft Cloud Holdings Limited
Aug 20, 2025, 07:00 ET ZIM Reports Financial Results for the Second Quarter of 2025
JUN-30-25 DEC-31-24
More news about: ZIM Integrated Shipping Services Ltd.
Aug 20, 2025, 06:00 ET Pixelworks Empowers realme P4 Series Smartphones to Deliver Flagship Visual Display Performance
benefit the entire ecosystem with better informed game developers, players, and reviewers." Commenting on this cooperation, Jun Fang, Vice President of Pixelworks and General Manager of Mobile Business Unit, stated, "With the flagship-like performance and attractive cost
More news about: Pixelworks, Inc.
Aug 20, 2025, 05:43 ET Dubai Humanitarian: Powerful New Documentary Reveals World's Largest Humanitarian Logistics Hub
https://www.youtube.com/watch?v=cjKME2Sj3-c. Dubai Humanitarian aid in numbers (Jan to Jun 2025) $48.8mAid worth $48,867,298 distributed from
More news about: Dubai Humanitarian
Aug 19, 2025, 10:00 ET Jaypirce® (pirtobrutinibe) da Lilly, o primeiro e único inibidor de BTK não covalente (reversível) aprovado, atingiu seu desfecho primário em um estudo de Fase 3 comparativo com ibrutinibe em LLC/SLL
doi:10.1016/S0140-6736(21)00224-5 8 Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J Hematol Oncol. 2020;13(1):79. Published 2020 Jun 17. doi:10.1186/s13045-020-00914-1 9 Gu D, Tang H, Wu J, Li J, Miao Y. Targeting Bruton tyrosine kinase using non-covalent inhibitors
More news about: Eli Lilly do Brasil
Aug 19, 2025, 08:35 ET WuXi Biologics Reports Solid 2025 Interim Results
is expected to close in the fourth quarter of 2025. BacklogAs of Jun 30, 2025, total backlog increased to US$20.34 billion, comprising US$11.35 billion
More news about: WuXi Biologics
Aug 18, 2025, 17:24 ET Quiet Beauty: entenda a tendência estética que respeita resultados minimalistas e mais naturais
tecidual.F. Avaliação 12meses após última aplicação de PLLA-SCA 1. Weiss RA et al. Dermatol Surg. 2016 Jun;42(6):699-7092. Di Gregorio C et al. Clin Cosmet Investig Dermatol. 2022 Apr 14;15:681-690.3.
More news about: Galderma
Aug 18, 2025, 09:00 ET Dx&Vx旗下子公司Avixgen與美國生物技術公司就新一代藥物遞送平台達成3.6億美元技術許可協議
Dx&Vx與Avixgen作為韓國生物科技領域肽類藥物遞送技術開發的領軍企業，已基於多個多肽平台構建起完善的療法與遞送技術體系。 此次協議僅涉及ACP平台卓越擴展性的極小部分應用權利，血腦屏障相關專利亦不在授權之列。即便如此，雙方仍達成3.6億美元首付加里程碑款項的交易規模，堪稱重大商業突破。 Avixgen首席執行官Sung Jun Han表示：「此次全球技術許可協議是我們公司的首個此類協議，代表著多年持續研發努力的成果。我們感謝合作夥伴對我們技術價值的認可，期待以此為契機，加速全球市場佈局並進一步擴大合作。」 Dx&Vx首席執行官Kevin Kwon稱：「憑借成熟的業務拓展能力，我們成功展示了子公司技
More news about: Dx&Vx
Aug 18, 2025, 09:00 ET Avixgen, a subsidiary of Dx&Vx, signs a licensing-out agreement worth USD 360 million with a U.S. biotech company for its next-generation drug delivery platform (ACP).
USD 360 million in upfront and milestone payments is considered a very encouraging result. Sung Jun Han, CEO of Avixgen, said, "This global licensing-out agreement is the first for our company and represents the fruition of years of continuous
More news about: Dx&Vx
Aug 18, 2025, 00:40 ET GC Biopharma Signs MOU with Thai Red Cross Society to Strengthen Collaboration on Plasma-Derived Therapies
[email protected] Yelin Jun[email protected] Yoonjae Na
More news about: GC Biopharma
Aug 14, 2025, 07:24 ET Sustaining Operational Excellence and Financial Strength, Nava Advances on Strategic Growth Projects
Jun-25 Jun-24 YoY%
More news about: Nava Limited
Aug 14, 2025, 06:30 ET Allot Announces Second Quarter 2025 Financial Results
Jun. 2025: 25.2
More news about: Allot Ltd.
Aug 14, 2025, 02:28 ET Implantica publishes Interim Report January - June 2025 (Q2)
https://mb.cision.com/Public/19732/4217816/b64ef09f6f91a4ba.pdf Implantica publishes Interim Report Jan - Jun 2025 Q2
More news about: Implantica
Aug 13, 2025, 08:00 ET BioDlink Accelerates Global Expansion with Bevacizumab Launch in Colombia and Pakistan
cancer[3], which has seen a global increase in early-onset cases in middle- and low‑income countries," said Dr. Jun Liu, CEO and Executive Director of BioDlink. "With our partnership with Kexing Biopharm, we are committed to serving South American and other
More news about: BioDlink Biopharm Co., Ltd.
Aug 13, 2025, 07:08 ET Ecopetrol publishes financial results for second Quarter 2025
Dry Jun 3/2025 6
More news about: Ecopetrol S.A.
Aug 13, 2025, 04:45 ET Ekshibitor yang Sangat Mendunia, ITE HONG KONG 2026 Menjangkau GBA dan Wilayah Lain di Asia
Liburan ke Luar Negeri (2025) Jan–Jun Jul-Des
More news about: ITE Hong Kong
Aug 13, 2025, 01:06 ET SEG Solar dan PT ATW Modul Manufaktur Jalin Kemitraan Distribusi Eksklusif guna Mempercepat Tingkat Pemanfaatan Solusi Tenaga Surya PV di Indonesia
SEG Solar kini memasuki Fase 2 dalam strategi investasi dan lokalisasi di Indonesia," ujar Jun Zhuge, Founder & Chief Operating Officer, SEG Solar. "Kolaborasi yang terjalin dengan AMM memperkuat komitmen kami untuk menyediakan
More news about: SEG Solar
Aug 12, 2025, 16:05 ET Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Company).2 Source: Viatris Customer Demand (Q2'25).3 Source: IQVIA DDD, HDS, VA and Non-Reporting Hospital through Jun '25.4 Non-GAAP profit (loss) consists of GAAP net income (loss) before taxes less (i) share-based compensation expense, (ii) non-cash
More news about: Theravance Biopharma, Inc.